您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > CL 82198 hydrochloride
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
CL 82198 hydrochloride
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CL 82198 hydrochloride图片
CAS NO:307002-71-7
包装与价格:
包装价格(元)
10mg电议
50mg电议

产品介绍
CL 82198 hydrochloride 是 MMP-13 的选择性抑制剂。
Cas No.307002-71-7
化学名N-(4-morpholin-4-ylbutyl)-1-benzofuran-2-carboxamide;hydrochloride
Canonical SMILESC1COCCN1CCCCNC(=O)C2=CC3=CC=CC=C3O2.Cl
分子式C17H33N2O3.HCl
分子量338.83
溶解度DMF: 3 mg/ml,DMSO: 2.5 mg/ml,Ethanol: 25 mg/ml,PBS (pH 7.2): 0.25 mg/ml
储存条件Desiccate at RT
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

IC50: 89% inhibition at 10μg/mL

CL 82198 is a selective MMP-13 inhibitor.

Matrix metalloproteinases (MMPs) are involved in the degradation of the extracellular matrix associated with normal tissue remodeling processes such as wound healing, pregnancy, and angiogenesis. Expression and activity of MMPs is highly controlled due to their degradative nature where the apparent loss in this regulation leads to the pathological destruction of connective tissue and the ensuing disease state.

In vitro: CL-82198 was identified as a weak inhibitor against MMP-13 and demonstrated no activity against MMP-1, MMP-9, or the related enzyme TACE. Bearing drug-like properties, CL-82198 was regarded as an ideal candidate for optimization of enzyme potency and selectivity. In NMR binding studies, it was shown that CL-82198 bound within the entire S1’ pocket of MMP-13, which was the basis of its selectivity against MMP-1, MMP-9, and TACE [1].

In vivo: To investigate the contribution of MMP-13 down-regulation during gastroprotection by acetaminophen, the effects of CL-82198 on IBP-induced gastric damage were evaluated. Results showed that CL-82198 decreased gastric lesions in a dose-dependent manner in the presence of IBP. Compared with IBP administration alone, CL-82198 administered at 0.2 and 1.0 mg/kg resulted in 40.3% and 72.1% decrease in gastric lesion, respectively [1].

Clinical trial: N/A

References:
[1] James M.  Chen,Frances C. Nelson,Jeremy I. Levin,Dominick Mobilio,Franklin J. Moy,Ramaswamy Nilakantan,Arie Zask,andRobert Powers. Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design. J. Am. Chem. Soc.,2000,122(40), pp 9648–9654
[2] Fukushima E,Monoi N,Mikoshiba S,Hirayama Y,Serizawa T,Adachi K,Koide M,Ohdera M,Murakoshi M,Kato H.  Protective effects of acetaminophen on ibuprofen-induced gastric mucosal damage in rats with associated suppression of matrix metalloproteinase. J Pharmacol Exp Ther.2014 Apr;349(1):165-73.